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from a 4 degree spacing to a 2 degree spacing. In this study we 
evaluated the effect of control point interpolation on the dose 
distribution in the patient and on plan delivery at the linac.  
Materials and Methods: VMAT plans to treat stage III lung tumours 
were created for 8 patients. All plans were optimized with a 4 degree 
control point spacing. When the plan was clinically acceptable the 
control point spacing was interpolated to 2 degrees. For both plans we 
compared the coverage of the 95% isodose of the PTV minus lung 
tissue,the PTV max dose, the mean lung dose, the lung V20 and the 
maximum dose in the myelum.  
Both plans (interpolated and original) were send to the record and 
verify system (MosaiQ) and irradiated on a cubic solid water phantom 
(30x30x20 cm) using an Elekta Synergy linac. The dose in the isocenter 
was verified using a pinpoint ionisation chamber. In a consecutive 
session, the dose in the coronal isocentric plane was measured using 
the Octavius detector 729. Monitor units per control point were scaled 
in Pinnacle using a script to compensate for the angular dependence 
of the sensitivity of the detector. For both types of plans we 
compared the results of the measurements and the duration of the 
treatment. To compare array measurements and planned dose we 
used a gamma criterion of 2mm/2%. The dosecriterion was taken 
relative to the isocentric dose in the phantom. Doses below 30% of the 
maximum measured dose were excluded from the gamma calculation. 
Results: Effects of control point interpolation on the PTV-lung 
coverage, mean lung dose and lung V20 were negligible. PTV max dose 
was on average 0,8% higher in the interpolated plans, with a maximum 
of 2,2%. The mean increase in the maximum dose in the myelum was 
0,1 Gy with a maximum of 0,4 Gy. 
The accuracy of the pinpoint measurements for the original and 
interpolated plans were not statistically significant: average 
difference between planned isocentric dose and measured dose was -
0,3% (SD 1,6%) for 4 degree control point spacing and -1,3% (SD 1,1%) 
for 2 degree control point spacing. 
For the 4 degrees per control point plans we measured an average 
gamma pass rate of 82,4% with the best plan having a pass rate of 
90,0% and the worst plan a 73,6% pass rate. For the interpolated plans 
the average pass rate was 82,2% while the best and worst plan had a 
pass rate of 89,0% and 70,8% respectively. 
Finally we also measured the delivery time of the original and 
interpolated plans and observed that interpolated plans always took 
longer to deliver with a mean delivery time of 103,5 seconds 
compared to 94,5 seconds for a 4 degree spacing plan. 
Conclusions: We observed that interpolation of control point spacing 
from 4 to 2 degrees does not increase the agreement of measurement 
and dose calculation. In addition, the effect on the DVH parameters is 
negligible while both the time needed for planning and delivery 
increases. We therefore refrain from using control point interpolation 
in our clinic. 
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Purpose/Objective: To retrospectively evaluate the influence of 
intravenous contrast agent on dose calculation in CT-based three-
Dimensional-Conformal-Radiation-Therapy (3D-CRT) for pelvis and 
head-and-neck cancer patients, using two different dose calculation 
algorithms, Dose-Volume Histograms (DVHs) and 3D gamma index 
analysis. 
Materials and Methods: We randomly selected 10 pelvis and 10 head-
and-neck patients, for which two sets of CT images were acquired in 
the same position, before and after intravenous contrast agent 
injection. CT-based planning was performed in Eclipse treatment 
planning system, version 10, using Analytical Anisotropic Algorithm 
(AAA), with a calculation grid of 2.5 mm, and applying heterogeneity 
correction. A radiation oncologist contoured the target volumes and 
organs at risk (OARs) on the CT images without contrast, after 
registering them with CT images with contrast. A treatment plan was 
performed on the CT scan without contrast, and then copied to the CT 
scan with contrast using the same planning data when recalculating 
the dose. Re-plans were similarly performed on Monaco treatment 
planning system, version 3.0, using a Monte Carlo (MC) dose 
calculation algorithm, with a calculation grid of 2.5 mm and 1% 
variance. DVHs from these plans were analyzed. 
The statistical data analysis was performed using the Wilcoxon 
matched pairs test; a p-value of < 0.05 was considered significant. A 
3D gamma index analysis was performed, and the differences in dose 
distribution between two plans evaluated, for various combinations of 
distance-to-agreement (DTA) of 1 mm, 2 mm, and 3 mm and dose 
difference criteria of 2%, 3%, 4%, and 5%. 
Results: DVH analysis showed no significant difference between with 
and without contrast CT treatment plans. 
 
Table 1. The mean and maximum percentage dose difference 
between CT images with and without contrast for pelvis and head-
and-neck patients  
 
 Percentage dose
difference 
(%) 
AAA 
algorithm 
(mean ± SD) 
p-
value 
MC 
algorithm 
(mean ± 
SD) 
p-value 
Pelvis cases (n = 10) 
PTV Mean  0.1 ± 0.4 > 0.2 0.2 ± 0.7 > 0.2 
Maximum 0.3 ± 0.9 > 0.2 0.4 ± 0.8 0.1 < p < 
0.2 
Rectum Mean  0.1 ± 0.4 > 0.2 0.1 ± 0.6 > 0.2 
Maximum 0.1 ± 0.4 > 0.2 0.4 ± 0.7 0.1 < p < 
0.2 
Bladder Mean  0.1 ± 0.4 > 0.2 0.1 ± 1 > 0.2 
Maximum 0.2 ± 0.6 > 0.2 0.2 ± 0.7 > 0.2 
Head-and-neck cases (n = 10) 
PTV 60 Mean  0.1 ± 0.4 > 0.2 0.3 ± 0.9 > 0.2 
Maximum 0.4 ± 0.7 > 0.2 0.4 ± 0.8 0.02 < p 
< 0.05 
PTV 54 Mean  0.1 ± 0.6 > 0.2 0.2 ± 0.4 > 0.2 
Maximum 0.1 ± 1.7 > 0.2 0.3 ± 0.8 0.05 < p 
< 0.1 
Spinal 
cord 
Mean  0.1 ± 0.4 > 0.2 0.1 ± 1.7 > 0.2 
Maximum 0.4 ± 1 > 0.2 0.4 ± 1.5 > 0.2 
Brain 
stem 
Mean  0.2 ± 0.6 > 0.2 0.2 ± 2.5 > 0.2 
Maximum 0.1 ± 0.5 > 0.2 1.1 ± 2.1 0.05 < p 
< 0.1 
Left 
parotid 
Mean  0.3 ± 0.9 > 0.2 1 ± 2.2 > 0.2 
Maximum 0.4 ± 0.7 > 0.2 0.6 ± 1.6 0.1 < p < 
0.2 
Right 
parotid 
Mean  0.3 ± 0.9 > 0.2 1.3 ± 1.7 > 0.2 
Maximum 0.4 ± 0.8 > 0.2 0.5 ± 1.6 0.02 < p 
< 0.05 
 
Figure 1. 3D Gamma analysis window showing the gamma distribution 
for MC dose calculation algorithm and representative pelvis (a) and 
head-and-neck (b) patients, as coronal view. The red areas represent 
the points failing gamma criteria for 2 mm DTA and 2% dose 
difference. 
(a) 
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(b)
 Figure 2. Gamma index analysis results for (a) pelvis and (b) head-
and-neck cases 
(a) 
 
(b) 
  
Conclusions: The presence of intravenous contrast agent does not 
significantly affect the dose calculation in CT-based 3D-CRT planning 
of pelvis and head-and-neck.  
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Purpose/Objective: The dosimetric aspects of radiotherapy treatment 
plan quality are evaluated with isodoses and dose volume histogram 
(DVH) values. Usually, the reporting consists in some particular values 
for target volumes (TV) and organs at risk (OAR). However, due to the 
complexity of the IMRT dose distributions, given a patient and 
treatment goals, several operators produce their own optimal plan 
depending on their experience and their tradeoffs between TV and 
OAR DVH endpoints. The aim of this study was (1) to evaluate the 
operator variability in our institution and (2) to improve the relevancy 
of the DVH endpoints. The study focused on Tomotherapy planning for 
head and neck cases. 
Materials and Methods: Ten patients with bilateral lymphatic node 
irradiation were selected from our database. Prescribed doses for 
planning target volumes PTV(tumor) and lymphatic nodes PTV(nodes) 
were 70Gy and 56Gy in 35 fractions respectively. For each patient, 
seven physicists of our department produced their own plan based on 
the same set of contours and the same treatment goals. For plan 
validation, DVH endpoints were related to the following organs: GTV 
(D98%), PTV(tumor) (D98%, D2%), PTV(nodes) D(98%), spinal cord 
(D2%), parotid glands (Dmean, V45Gy, V30Gy), larynx (V50Gy), oral 
cavity(V50Gy). The inter-operator variability was studied by 
comparing the DVH values. Three groups of values were evaluated (i) 
PTVs, (ii) principal OARs for which the respect of endpoints is 
mandatory and (iii) secondary OARs for which the respect of endpoints 
improves the patient quality of life. 
Results: Physicists had an experience with Tomotherapy planning 
software ranging from 1 to 5 years. 70 plans were generated and were 
evaluated by a single physician. For all patients, all plans were 
clinically acceptable despite some discrepancies. For group (i), the 
main difference concerned D98% for PTV(tumor) and PTV(nodes) that 
were lower for two planners. For group (ii), the D2% to the spinal cord 
never exceeded 38Gy. Large differences were observed but they were 
considered minor by the physician. For group (iii), experience and 
tradeoffs of the planners yielded different dosimetric results, 
especially in the larynx and in the ipsilateral parotid gland. This organ 
sparing can lead to an slight undercoverage of the PTV(tumor). 
Whatever the group, differences were particularly observed for the 
first patients studied, but were reduced during the study. 
Conclusions: This work showed inter-operator variability in 
Tomotherapy planning for head and neck cases. However, all plans 
were acceptable by the physician. This comparison allowed to better 
define the priority of the endpoints to evaluate the quality of a plan 
and to narrow the variability over the study.  
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Purpose/Objective: Volumetric-modulated arc therapy (VMAT) is a 
relatively new treatment modality, in which gantry rotation and 
speed, dose-rate and multileaf collimator (MLC) leaves motion vary 
simultaneously. The aim of the study was to compare conventional 
intensity modulated radiation therapy (IMRT) with VMAT plans for 
prostate cancers. 
Materials and Methods: Ten randomly selected patients with prostate 
cancer were included for the present study. Contours for each pts 
were drawn using our clinical protocol. For each patient, three plans 
were generated for treatment modalities using a 80 leaves MLC with 
the leaves of 10 mm (MLCi2 Elekta Synergy). All IMRT and VMAT plans 
were calculated for 6MV photons. IMRT plan were generated using 
Oncentra Master Plan (v 3.3), whereas VMAT plans were performed 
with Monaco (v 3.2). The dose prescription was 76 Gy in 38 fractions 
to the target volume with respect the dose volume criteria for the 
organ at risk (OAR) complied with QUANTEC recommendation. Dose-
volume parameters of the plans were evaluated according to Rapport 
ICRU No 81.  
Results: All techniques: IMRT as well as VMAT result in treatment 
plans which comply with our current applied clinical protocol. From 
the DVH data, target coverage achieved similar results for IMRT and 
VMAT (table1): V95% - 99,3±0,7% and 99,2±0,7% for IMRT and VMAT, 
respectively. The average dose were 102,5±3,2% for IMRT and 
102,4±3,3% for VMAT. For OAR all planning objectives were largely 
met. VMAT plans were superior for rectum in all dose-volume 
constraints (p<0.05). Similar results were achieved in dose-volume 
constraints for bladder. VMAT leads to the average reduction of about 
6 Gy for the mean dose for rectum and of about 11 Gy for mean dose 
for bladder comparing to IMRT. There were no statistical differences 
between IMRT and VMAT in mean and dose-volume parameters for 
femurs. The average MU were 452±.81,7, and 510.9±.50,6for IMRT and 
VMAT, respectively. 
Conclusions: VMAT achieved similar target coverage to IMRT plans for 
prostate cancer pts. It provided a better OAR sparing due to reduction 
of high-dose-receiving area of healthy tissue. Further studies are 
indicated to evaluated the VMAT impact on quality of life of prostate 
cancer pts during and after the therapy. 
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